Improved survival with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer aged 75 years or older: a subset of elderly patients in TREAD 01
Not Applicable
Recruiting
- Conditions
- SCLC
- Registration Number
- JPRN-UMIN000050553
- Lead Sponsor
- Shonan Fujisawa Tokushukai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Exclusion criteria for this study include: de novo EGFR T790M mutation, opt-outs who refused to give informed consent, insufficient data extraction such as missing details of previous cancer treatment at other hospitals or individual patient data, simultaneous or metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, or disease-free for 5 years or less.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method OS
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain osimertinib's improved survival in elderly EGFR-mutated NSCLC patients compared to standard-of-care therapies?
How does osimertinib compare to first-generation EGFR TKIs in elderly NSCLC patients within the TREAD 01 trial's observational design?
Which biomarkers correlate with osimertinib response in elderly EGFR-mutated NSCLC patients from the TREAD 01 subset analysis?
What adverse events are reported for osimertinib in elderly NSCLC patients, and how do they differ from younger populations in TREAD 01?
Are there combination therapies with osimertinib showing enhanced efficacy in elderly EGFR-mutated NSCLC patients beyond TREAD 01 findings?